Enlivex Therapeutics (ENLV) Short Interest Ratio & Short Volume $0.98 -0.05 (-4.87%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Enlivex Therapeutics Short Interest DataEnlivex Therapeutics (ENLV) has a short interest of 160,100 shares. This marks a 58.67% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.4, indicating that it would take 1.4 days of the average trading volume of 165,480 shares to cover all short positions.Current Short Interest160,100 sharesPrevious Short Interest100,900 sharesChange Vs. Previous Month+58.67%Dollar Volume Sold Short$216,135.00Short Interest Ratio1.4 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares21,410,000 sharesPercentage of Shares Shorted0.75%Today's Trading Volume388,159 sharesAverage Trading Volume165,480 sharesToday's Volume Vs. Average235% Short Selling Enlivex Therapeutics? Sign up to receive the latest short interest report for Enlivex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENLV Short Interest Over TimeENLV Days to Cover Over TimeENLV Percentage of Float Shorted Over Time Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Enlivex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/2024160,100 shares $216,135.00 +58.7%N/A1.4 $1.35 10/15/2024100,900 shares $156,395.00 -3.5%N/A1.1 $1.55 9/30/2024104,600 shares $175,728.00 -23.1%N/A1.4 $1.68 9/15/2024136,100 shares $213,677.00 +43.9%N/A1.9 $1.57 8/31/202494,600 shares $122,980.00 +26.6%N/A1.9 $1.30 8/15/202474,700 shares $91,134.00 -11.7%N/A1.3 $1.22 Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202484,600 shares $113,364.00 -27.4%N/A1.4 $1.34 7/15/2024116,500 shares $164,265.00 -0.6%N/A1.6 $1.41 6/30/2024117,200 shares $166,424.00 -16.8%N/A0.7 $1.42 6/15/2024140,800 shares $205,568.00 -10.5%N/A0.8 $1.46 5/31/2024157,300 shares $213,928.00 -31.8%N/A0.9 $1.36 5/15/2024230,600 shares $327,452.00 -12.4%N/A1.3 $1.42 4/30/2024263,200 shares $439,544.00 -5.6%N/A1.5 $1.67 4/15/2024278,700 shares $362,310.00 +17.9%N/A1.6 $1.30 3/31/2024236,400 shares $895,956.00 -9.6%N/A2.7 $3.79 3/15/2024261,500 shares $1.07 million +15.4%N/A2.4 $4.11 2/29/2024226,600 shares $703,593.00 +51.2%N/A2.2 $3.11 2/15/2024149,900 shares $481,179.00 -6.6%N/A1.6 $3.21 1/31/2024160,500 shares $449,400.00 -13.7%N/A1.9 $2.80 1/15/2024185,900 shares $533,533.00 +32.5%N/A2.3 $2.87 12/31/2023140,300 shares $378,810.00 +36.0%N/A1.8 $2.70 12/15/2023103,200 shares $145,512.00 -6.3%N/A1.9 $1.41 11/30/2023110,100 shares $202,584.00 -0.9%N/A3.5 $1.84 11/15/2023111,100 shares $194,425.00 -6.2%N/A3.6 $1.75 10/31/2023118,400 shares $157,472.00 +13.1%N/A3.9 $1.33 10/15/2023104,700 shares $147,627.00 -8.1%N/A4.1 $1.41 9/30/2023113,900 shares $179,962.00 +4.4%N/A4.5 $1.58 9/15/2023109,100 shares $206,199.00 +3.4%N/A4.2 $1.89 8/31/2023105,500 shares $252,145.00 -9.3%N/A4.8 $2.39 8/15/2023116,300 shares $303,543.00 +2.4%N/A5.1 $2.61 7/31/2023113,600 shares $290,816.00 +8.6%N/A4.9 $2.56 7/15/2023104,600 shares $248,948.00 +2.5%N/A4.8 $2.38 6/30/2023102,100 shares $268,247.33 -20.2%N/A3.6 $2.63 6/15/2023128,000 shares $362,240.00 +5.6%N/A3.6 $2.83 5/31/2023121,200 shares $316,332.00 -5.8%N/A3.5 $2.61 5/15/2023128,700 shares $359,073.00 -1.2%N/A3.8 $2.79 4/30/2023130,200 shares $369,768.00 -4.6%N/A3.7 $2.84 4/15/2023136,400 shares $396,924.00 -15.7%N/A3.6 $2.91 3/31/2023161,700 shares $588,588.00 +0.5%N/A4.3 $3.64 3/15/2023160,900 shares $577,631.00 -1.3%N/A5.9 $3.59New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 2/28/2023163,000 shares $652,000.00 +0.9%N/A5.7 $4.00 2/15/2023161,500 shares $673,455.00 -8.8%N/A5.5 $4.17 1/31/2023177,100 shares $775,698.00 -2.9%N/A5.8 $4.38 1/15/2023182,300 shares $796,505.16 -4.8%N/A6.9 $4.37 12/30/2022191,400 shares $753,637.50 -0.5%N/A7.8 $3.94 12/15/2022192,400 shares $779,220.00 -11.5%N/A9.2 $4.05 11/30/2022217,500 shares $996,998.25 +16.9%N/A9 $4.58 11/15/2022186,000 shares $894,660.00 +0.1%N/A6.9 $4.81 10/31/2022185,800 shares $797,082.00 -3.8%N/A6.6 $4.29 10/15/2022193,100 shares $805,227.00 +1.2%N/A5.4 $4.17 9/30/2022190,900 shares $811,325.00 +4.5%N/A4.4 $4.25 9/15/2022182,700 shares $959,175.00 -5.4%N/A3.9 $5.25 8/31/2022193,100 shares $1.01 million -7.0%N/A4.2 $5.25 8/15/2022207,700 shares $1.08 million -9.5%N/A4.4 $5.22 7/31/2022229,600 shares $975,800.00 -8.4%N/A4 $4.25 7/15/2022250,600 shares $1.23 million -9.8%N/A3.8 $4.91 6/30/2022277,700 shares $1.26 million -2.3%N/A3.5 $4.52 6/15/2022284,300 shares $1.16 million -0.3%N/A3.5 $4.07 5/31/2022285,000 shares $1.43 million -9.2%N/A3.5 $5.01 5/15/2022313,900 shares $1.34 million -9.6%N/A4.1 $4.28 4/30/2022347,200 shares $1.98 million -3.9%N/A4.7 $5.69 4/15/2022361,300 shares $2.67 million +15.0%N/A5.9 $7.39 3/31/2022314,200 shares $1.76 million -2.2%N/A5.3 $5.59 3/15/2022321,300 shares $1.63 million -10.4%N/A5.3 $5.06 2/28/2022358,500 shares $1.92 million -4.0%N/A4.9 $5.35 2/15/2022373,500 shares $1.99 million +2.8%N/A4.7 $5.34 1/31/2022363,200 shares $1.94 million +8.2%N/A4.2 $5.34 1/15/2022335,700 shares $1.97 million -8.3%N/A3.7 $5.87 12/31/2021365,900 shares $2.29 million +0.1%N/A4.2 $6.25 12/15/2021365,400 shares $2.40 million -3.6%N/A4.4 $6.56 11/30/2021379,000 shares $2.65 million +7.0%N/A5 $7.00 11/15/2021354,200 shares $2.91 million +9.9%N/A3.5 $8.21 10/29/2021322,200 shares $2.65 million +4.5%N/A1 $8.24 10/15/2021308,300 shares $2.86 million -13.0%N/A0.9 $9.28 9/30/2021354,300 shares $3.50 million -8.0%N/A1.1 $9.88 9/15/2021385,200 shares $4.21 million -8.0%N/A1.2 $10.92 8/31/2021418,500 shares $5.80 million +114.2%N/A1.3 $13.86 8/13/2021195,400 shares $1.99 million +38.0%N/A0.7 $10.17 7/30/2021141,600 shares $1.08 million No Change1.2%2.1 $7.60 7/15/2021141,600 shares $1.07 million +0.9%1.2%1.8 $7.54 6/30/2021140,400 shares $1.25 million +4.0%1.2%1.6 $8.90 6/15/2021135,000 shares $1.32 million +14.9%1.1%1.5 $9.80 5/28/2021117,500 shares $1.10 million -28.6%1.0%1.1 $9.37 5/14/2021164,500 shares $1.42 million +26.4%N/A1.1 $8.61 4/30/2021130,100 shares $1.57 million +94.2%N/A0.3 $12.10 4/15/202167,000 shares $725,610.00 -18.8%N/A0.2 $10.83 3/31/202182,500 shares $874,500.00 -17.6%N/A0.2 $10.60 3/15/2021100,100 shares $1.44 million +5.2%1.0%0.2 $14.40 2/26/202195,200 shares $1.44 million +64.4%1.1%0.2 $15.11 2/12/202157,900 shares $1.22 million -76.6%0.7%0.1 $21.09New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 1/29/2021246,900 shares $2.93 million +13.8%3.2%0.7 $11.85 1/15/2021217,000 shares $2.23 million +7.1%2.9%1 $10.29 12/31/2020202,600 shares $1.87 million -24.9%2.7%0.7 $9.22 12/15/2020269,700 shares $2.65 million +165.2%3.5%0.2 $9.83 11/30/2020101,700 shares $876,654.00 -38.2%1.3%0.1 $8.62 11/15/2020164,600 shares $1.53 million -13.1%2.2%0.1 $9.28 10/30/2020189,500 shares $2.23 million -53.7%2.5%0.2 $11.75 10/15/2020408,900 shares $5.41 million +1,497.3%5.4%0.4 $13.23 9/30/202025,600 shares $152,064.00 +22.5%0.3%0 $5.94 9/15/202020,900 shares $108,262.00 -57.1%0.3%0.3 $5.18 8/31/202048,700 shares $252,753.00 +429.4%0.6%0.5 $5.19 8/14/20209,200 shares $48,668.00 -59.1%0.1%0.1 $5.29 7/31/202022,500 shares $122,850.00 +10.3%0.3%0.2 $5.46 7/15/202020,400 shares $104,040.00 +88.9%0.3%0.2 $5.10 6/30/202010,800 shares $65,448.00 -6.1%0.1%0.1 $6.06 6/15/202011,500 shares $62,560.00 -48.0%0.2%0.1 $5.44 5/29/202022,100 shares $117,130.00 +71.3%0.3%0.2 $5.30 5/15/202012,900 shares $62,178.00 +152.9%0.2%0.1 $4.82 4/30/20205,100 shares $27,999.00 -67.1%0.1%0 $5.49 4/15/202015,500 shares $86,800.00 -17.6%0.2%0.1 $5.60 3/31/202018,800 shares $105,468.00 -69.6%0.3%0.1 $5.61 3/13/202061,900 shares $282,264.00 +302.0%1.4%0.2 $4.56 2/28/202015,400 shares $63,448.00 -54.0%0.3%0.1 $4.12 2/14/202033,500 shares $192,960.00 +805.4%0.8%0.5 $5.76 1/31/20203,700 shares $31,450.00 -32.7%0.1%0.2 $8.50 1/15/20205,500 shares $45,100.00 +10.0%0.1%0.2 $8.20 12/31/20195,000 shares $45,500.00 +11.1%0.1%0.1 $9.10 ENLV Short Interest - Frequently Asked Questions What is Enlivex Therapeutics' current short interest? Short interest is the volume of Enlivex Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 160,100 shares of ENLV short. Learn More on Enlivex Therapeutics' current short interest. What is a good short interest ratio for Enlivex Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENLV shares currently have a short interest ratio of 1.0. Learn More on Enlivex Therapeutics's short interest ratio. Is Enlivex Therapeutics' short interest increasing or decreasing? Enlivex Therapeutics saw a increase in short interest in October. As of October 31st, there was short interest totaling 160,100 shares, an increase of 58.7% from the previous total of 100,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Enlivex Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Enlivex Therapeutics: Genelux Co. (5.15%), 23andMe Holding Co. (7.86%), CASI Pharmaceuticals, Inc. (1.90%), FibroBiologics, Inc. (8.79%), PMV Pharmaceuticals, Inc. (1.94%), Oncolytics Biotech Inc. (3.65%), Ikena Oncology, Inc. (0.44%), Quince Therapeutics, Inc. (7.33%), Clearside Biomedical, Inc. (2.32%), Chimerix, Inc. (1.90%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Enlivex Therapeutics stock? Short selling ENLV is an investing strategy that aims to generate trading profit from Enlivex Therapeutics as its price is falling. ENLV shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enlivex Therapeutics? A short squeeze for Enlivex Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ENLV, which in turn drives the price of the stock up even further. How often is Enlivex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENLV, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Genelux Short Squeeze 23andMe Short Squeeze CASI Pharmaceuticals Short Squeeze FibroBiologics Short Squeeze PMV Pharmaceuticals Short Squeeze Oncolytics Biotech Short Squeeze Ikena Oncology Short Squeeze Clearside Biomedical Short Squeeze Chimerix Short Squeeze PDS Biotechnology Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENLV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.